Ziccum enters into evaluation agreement with global pharmaceutical and vaccine company
Stockholm, October 3, 2019. Ziccum AB (publ) (‘Ziccum’) is to conduct an evaluation study with a global healthcare company engaged in researching and developing, vaccines and proteins to combat infectious diseases. The project will explore whether Ziccum’s air-drying capabilities could generate stable, dry-form vaccines for the company. 1-in-5 children worldwide currently do not receive even basic vaccines (WHO), and 1.5 million die every year from vaccine-preventable diseases.
“We’re very proud to be starting this pilot project for such a prestigious and committed pharma company”, says Ziccum CEO Göran Conradson. “It’s a global company based in Europe who is committed to helping people be healthier by supporting better access and care in more places around the world. If our technology could be a part of that we would of course be delighted.”
“The pilot project collaboration is the second in just months”, Ziccum’s Chairman Fredrik Sjövall points out. “We clearly told the market that our first-year goal as a listed company was to partner on three pilot studies looking at developing stable, dry form vaccines and biologics. We’ve delivered on that promise. This is the second industrial collaboration we have announced in just a couple of months, and we see growing commercial interest in LaminarPaceTM moving forward. The world’s need to be able to deliver vaccines beyond the cold chain, to where they’re really needed, is urgent and growing. We’re convinced that our proprietary LaminarPaceTM technology may come to play an important part”.
LaminarPace enables the air-drying of delicate biologic drugs such as proteins, peptides and vaccines at room temperature, keeping the active ingredient intact. This capability could enable the development of new, stable, dry powder formulations of vaccines and biologic therapies that do not require costly global refrigeration supply chains to be transported and administered coast-effectively to any climate in the world.
For more information about Ziccum, please contact:
Göran Conradson: CEO Ziccum AB
E-mail: conradson@ziccum.com
Mob: +46 709 61 55 99
About Ziccum
Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets – and open up new ones. Ziccum’s share is traded on Spotlight Stockmarket. www.ziccum.com
The information above was provided for publication on October 3, 2019 (20.00 hours) by Ziccum AB (publ) according to EU Market Abuse Regulations, through the above contact person.
Tags: